 |
|
New intranasal influenza vaccine triggers robust immunity with significantly less antigen
October 29, 2008A single administration of a novel, nasally delivered influenza vaccine elicited immune responses in ferrets that were more than 20 times higher than those generated by two injections of the currently approved vaccines, according to a study by NanoBio Corporation. The new vaccine used only half the standard antigen dose to produce this effect.
Results of the study are being presented today at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.
The company's nasal vaccines exert adjuvant activity without the need for pro-inflammatory materials, toxins or cytokines.
"Our nanoemulsion-based intranasal vaccine adjuvant system represents a paradigm shift in vaccinology. It can be used to safely deliver multiple antigen types directly into the lining of the nasal mucosa, which is rich in dendritic cells that present the antigen(s) to the immune system," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "The nanoemulsion adjuvant uniquely interacts with these cells to trigger unparalleled mucosal and systemic immunity."
In the study, ferrets received 7.5, 15 and 45 micrograms of nanoemulsion-adjuvanted influenza vaccine (n=12 ferrets/dose). All three doses produced antibody responses substantially higher than those triggered by the standard intramuscular vaccine. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live influenza virus, and all were protected.
"A large, unmet medical need still exists for protecting people from influenza infection," Baker said. "The robust immunity and antigen-sparing capability demonstrated in this study are especially important for addressing this unmet need, as are the demands for a vaccine that would protect people in the face of a flu pandemic."
NanoBio plans to begin a phase 1 clinical study for seasonal influenza in the first half of 2009 and is currently initiating preclinical studies in pandemic flu.
MedThink Communications
"Our nanoemulsion-based intranasal vaccine adjuvant system represents a paradigm shift in vaccinology. It can be used to safely deliver multiple antigen types directly into the lining of the nasal mucosa, which is rich in dendritic cells that present the antigen(s) to the immune system," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "The nanoemulsion adjuvant uniquely interacts with these cells to trigger unparalleled mucosal and systemic immunity."
In the study, ferrets received 7.5, 15 and 45 micrograms of nanoemulsion-adjuvanted influenza vaccine (n=12 ferrets/dose). All three doses produced antibody responses substantially higher than those triggered by the standard intramuscular vaccine. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live influenza virus, and all were protected.
"A large, unmet medical need still exists for protecting people from influenza infection," Baker said. "The robust immunity and antigen-sparing capability demonstrated in this study are especially important for addressing this unmet need, as are the demands for a vaccine that would protect people in the face of a flu pandemic."
NanoBio plans to begin a phase 1 clinical study for seasonal influenza in the first half of 2009 and is currently initiating preclinical studies in pandemic flu.
MedThink Communications
Influenza Vaccine Current Events and Influenza Vaccine News RSSWorksite wellness programs may reduce employee absenteeism
Emory University Rollins School of Public Health researchers will present Nov. 11 on a range of topics at the American Public Health Association's annual meeting in Philadelphia, including a study that found reduced absenteeism among employees participating in a large-scale worksite wellness program.
Initial Results Show Pregnant Women Mount Strong Immune Response To One Dose of 2009 H1N1 Flu Vaccine
Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.
Flu vaccine given to women during pregnancy keeps infants out of the hospital
Infants born to women who received influenza vaccine during pregnancy were hospitalized at a lower rate than infants born to unvaccinated mothers.
Flu shots not to be sneezed at
Two in five at-risk American adults who would benefit from vaccination against seasonal flu are missing out on the protective shots because they believe they do not need them and are not inclined to be vaccinated.
NIH launches 2009 H1N1 influenza vaccine trials in HIV-infected pregnant women
The first clinical trials to test whether the 2009 H1N1 influenza vaccine can safely elicit a protective immune response in pregnant women launched yesterday, and a trial to conduct the same test in HIV-infected children and youth will begin next week.
NIH prepares to launch 2009 H1N1 influenza vaccine trial in people with asthma
The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.
Early results: In children, 2009 H1N1 influenza vaccine works like seasonal flu vaccine
Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Early results from clinical trials of 2009 H1N1 influenza vaccines in healthy adults
We are encouraged by reports that are now emerging from various clinical trials of 2009 H1N1 influenza vaccines, conducted by various vaccine manufacturers.
GEN reports on efforts to quickly develop swine flu vaccine
Scientists around the world are accelerating their efforts to develop a vaccine against the H1N1 influenza virus (Swine flu) as rapidly as possible, reports Genetic Engineering & Biotechnology News (GEN).
Universal flu vaccine holds promise
An influenza vaccine that protects against death and serious complications from different strains of flu is a little closer to reality, Saint Louis University vaccine researchers have found.
More Influenza Vaccine Current Events and Influenza Vaccine News Articles
 |
Influenza Vaccines for the Future (Birkhäuser Advances in Infectious Diseases) by Rino Rappuoli (Editor), Giuseppe Del Giudice (Editor) The threat constituted by the multiple outbreaks of avian influenza during the last few years is urgently calling for the development of new influenza vaccines. Fortunately, a quantum leap in technology has revolutionized the study of influenza and the engineering of new vaccine strains by reverse genetics. This volume provides a historical background and state-of-the-art information about the recent advances in the biology of influenza and the design of new influenza vaccines. |
 |
Progard 5 Vaccine - 25 Dose Package by INTERVET THIS VACCINE CANNOT BE SHIPPED TO MINNESOTA. A modified live virus vaccine used to vaccinate healthy dogs against distemper (Onderstepoort strain), hepatitis caused by CAV-1 and tracheobronchitis caused by CAV-2 (CAV-2 Manhattan strain cross-protects), parainfulenza and parvovirus infection (strain 154). Directions: 1 ml dose intramuscularly or subcutaneously at 6 weeks of age. Repeat every 3 to 4 weeks until 12 to 16 weeks of age. Dogs over 12 weeks of age should be vaccinated twice 3 to 4 weeks apart. Do not freeze. Avoid vaccinating pregnant bitches. An annual booster is recommended. |
 |
What your doctor wants you to know about flu virus vaccine. The weapon to combat and control epidemic influenza. ..... 1947 Rexall Drugs Ad, A5254A. 19470929 This Item is an original Magazine ad, taken from a vintage magazine of the year indicated. The ad is suitable for framing and displaying in your home or office. The scan of this item was taken through plastic film, however it is an accurate representation of the item. The nominal size is 10.5 inches by 14 inches. |
 |
Sovereign Silver 2 oz Fine Mist Spray by Natural Immunogenics Benefits of Sovereign Silver Bio-Active Silver Hydrosol- To support your immune system for all of its needs, choose Sovereign Silver Bio Active Hydrosol the #1 Selling silver supplement in America.* It has a unique combination of five benefits no other manufacturer can match: 1. Actively Charged (Bio-Active) 2. Easily Absorbed 3. Less Is More 4. Perfectly Safe. 5. 99.999% PURE |
 |
60 Minutes - H1N1 (November 1, 2009) Airdate 11/01/09 Where is the vaccine that was supposed to save the nation from the H1N1 virus? Almost 100 people have died from the virus, hospitalizations are on the rise, but the vaccine is still in short supply. Health and Human Services Secretary Kathleen Sebelius tells Scott Pelley that it won't be long before everyone who wants the vaccine will get the vaccine, and she says it is safe and effective. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Homeocare Labs Cold & Flu Relief, 0.3 ounces Tubes (Pack of 2) by Homeocare Labs For the temporary relief of minor fever, chills, runny nose, congestion, body aches and fatigue due to the common cold or the flu. |
 |
The Truth About Flu Vaccines Directed By: ITV Also With: ITV (Producer) |
 |
Vaccines for Pandemic Influenza (Current Topics in Microbiology and Immunology) by Richard W. Compans (Editor), Walter A. Orenstein (Editor) The recent outbreak of disease caused by a novel H1N1 virus has focused global attention on the threat of a new influenza pandemic. Recent years have also seen unprecedented outbreaks of avian influenza A viruses. In particular, highly pathogenic H5N1 viruses have not only resulted in widespread outbreaks in domestic poultry, but have been transmitted to humans resulting in numerous fatalities. The rapid expansion in the geographic distribution of these novel viruses raises the risk that such a virus could cause a global pandemic with high morbidity and mortality. An effective influenza vaccine represents the best approach to prevent and control such an emerging pandemic. However, current influenza vaccines are directed at existing seasonal influenza viruses, which have... |
 |
Warning Swine Flu Test Subject Keep Back Sign Logo Men's Tee Short Sleeve Size XL White by 99 Volts |
|
Pandemic influenza A (H1N1) vaccines, antivirals.(DRUGS, PREGNANCY, AND LACTATION): An article from: OB GYN News by Christina Chambers (Author) This digital document is an article from OB GYN News, published by International Medical News Group on October 1, 2009. The length of the article is 812 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Pandemic influenza A (H1N1) vaccines, antivirals.(DRUGS, PREGNANCY, AND LACTATION) Author: Christina Chambers Publication: OB GYN News (Magazine/Journal) Date: October 1, 2009 Publisher: International Medical News Group Volume: 44 Issue: 12 Page: 20(1) Distributed by Gale, a part of Cengage... |
| © 2009 BrightSurf.com |